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Abstracts
There are multiple screening and testing tools for os-
teoporosis. We need to understand the most cost-efficient
way to utilize these tools to identify postmenopausal
women with osteoporosis. The objective of this study was
to identify efficient strategies for detecting low bone mass
in postmenopausal women and estimate the incremental
cost per case found.
METHODS: The study sample consists of 392 women age
>50. Each participant completed the Simple Calculated
Osteoporosis Risk Estimation (SCORE':') (a prescreening
questionnaire), and bone mineral density (BMD) levels
were collected at different skeletal sites. Assumed costs
were: $5 for SCORE, $35 for peripheral site (pDXA) test-
ing at the forearm, $120 for single central (DXA) site test-
ing at hip or spine, and $200 for multiple site DXA. An os-
teoporotic woman was defined as a woman with BMD
< - 2 SD below peak adult mean at any site.
RESULTS: The cost, efficient frontier consisted of 7 strate-
gies ranging in cost from $33 to $189 per patient, with
corresponding sensitivity of 53% to 100%. The incremen-
tal cost per case found ranged from $62.30 to $1,100.
Most importantly, the current gold standard (testing all
women at the hip and spine) is not on the efficient frontier.
CONCLUSION: The efficiency of osteoporosis testing
can be greatly increased through the appropriate use of
sequential instruments to identify postmenopausal
women with osteoporosis.
" SCORE is a trademark of Merck & Co., Inc.
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OBJECTIVE: To develop and validate SF-12 osteoarthri-
tis-specific health index (SF-12 OASHI).
METHODS: Patient data on SF-12 and six osteoarthritis
(OA) clinical variables (physician and patient global as-
sessments, pain intensity, knee pain on weight bearing
and motion, time to walk 50 feet) at baseline and week 6,
from two placebo-controlled clinical trials (n = 422), as-
sessing efficacy of NSAIDs in OA patients were used. Us-
ing canonical correlation analysis, a SF-12 OASHI was
developed in 75% of the sample (n = 317) by adding in-
dividual SF-12 item scores at baseline, each multiplied by
their respective OA specific weights (canonical cross-
loadings on clinical variables). Validation (developmental
sample) and cross-validation (25% holdout sample [n =
105], and another clinical trial sample [n = 170]) of the
SF-12 OASHI were conducted by examining its correla-
tion with clinical variables, and by computing the relative
validity (RV) estimates of SF-12 OASHI as compared to
physical (PCS12) and mental component summary scores
(MCS12), using baseline and change scores at 6 weeks.
Correlation between SF-12 component score and clinical
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variable was divided by correlation between OASHI and
respective clinical variable to arrive at the RV.
RESULTS: SF-12 OASHI demonstrated significant corre-
lations with individual clinical variables ranging from
-0.19 to -0.54 (p < 0.05). In general, SF-12 OASHI was
more sensitive than the PCS12 and MCS12 scores as indi-
cated by higher correlation coefficients with clinical vari-
ables, at baseline, in developmental and two cross-valida-
tion samples. At baseline, the RV coefficients for SF-12
OASHI ranged from 0.64 to 1.09 for PCS12 and 0.37 to
0.89 for MCS12. In general, SF-12 OASHI also showed
more responsiveness to changes in clinical variables at 6
weeks as compared with PCS12 and MCS12 scores.
CONCLUSION: The SF-12 OA-specific health index is a
comprehensive and more sensitive measure of patient
quality of life in OA as compared with PCS12 and
MCS12.
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OBJECTIVE: To evaluate psychometric properties of SF-
12 as a generic health-related quality of life (HQL) mea-
sure in a patient population with osteoarthritis (OA) in
clinical trials.
METHODS: Data were aggregated from three clinical
trials, evaluating efficacy of different NSAIDs in OA pa-
tients (n = 651). Patient assessments were made using SF-36
and seven commonly used clinical measures in OA (pa-
tient and physician global assessments, pain intensity,
time to walk 50 feet, knee pain on weight bearing and
motion, functional capacity classification), at baseline,
week 2, and week 6. The SF-12 items were extracted
from the SF-36 items. For the SF-12, item missing rate,
computability of component scores, factor structure, item
convergent/discriminant validity, item-component corre-
lations, and floor and ceiling effects were evaluated. Cor-
relations of SF-12 physical (PCS12) and mental compo-
nent summary scores (MCS12) with SF-36 component
summary scores (PCS36 and MCS36), and clinical vari-
ables were used to establish construct and convergent va-
lidity of the SF-12 in OA patients.
RESULTS: A low individual SF-12 item missing rate
(0.46% to 2.3%) and a high percentage score computa-
bility (91 %) were observed at baseline. No floor or ceil-
ing effects at baseline, week 2, and week 6 were observed.
The scree plot confirmed two factor structure of the SF-12
items. Items belonging to the physical component corre-
lated more strongly with the PCS12 than the MCS12, and
vice versa. The correlations between PCS12 and PCS36,
and MCS12 and MCS36 ranged from 0.94 to 0.96 (p <
0.0005), at baseline, week 2, and week 6. Significant cor-
relations of -0.18 to -0.53 (p < 0.05) between SF-12
